ASAHI KASEI PHARMA

Contact us

AsahiKASEI

Why Partner with Us

Who We Are

Asahi Kasei Pharma Corporation is an R&D-based pharmaceutical company headquartered in Tokyo, Japan, specializing in the therapeutic areas of autoimmune, musculoskeletal, pain management, severe infectious diseases, and specialty field (ICU, refractory hematologic or gastrointestinal disorders).

Proven Record of Successful Partnerships

We have successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir™ (famciclovir), Flivas™ (naftopidil), Toledomin™ (milnacipran hydrochloride), Reclast™ (zoledronic acid), Kevzara® (sarilumab), Plaquenil® (hydroxychloroquine sulfate), Cresemba™ (isavuconazonium sulfate), Doptelet® (avatrombopag maleate) and Empaveli® (pegcetacoplan).

  • Commercial Access in Japan, East Asia, and the U.S.

    Asahi Kasei Pharma fields an experienced, nationwide sales force in Japan.
    In 2020, Veloxis Pharmaceuticals, a U.S.based specialty pharmaceutical company committed to improving the lives of transplant patients, has joined Asahi Kasei Group, enabling us to establish a U.S. commercial foundation.
    We also have commercial access to other pharmaceutical markets in East Asia through our China affiliate, Asahi Kasei Pharma (Beijing) Co., Ltd. (AKPB), as well as partners in China, Korea.

  • Clinical Development/Regulatory Affairs Management in Japan, China, and Worldwide

    We have a well-established record of managing clinical trials and successfully obtaining product marketing approvals in Japan.
    We manage our clinical development and regulatory affairs activities in China through AKPB.
    We manage our global clinical development activities and regulatory submissions outside of Japan and China in collaboration with Veloxis Pharmaceuticals.

  • Research Capabilities

    We have a fully integrated research function and conduct preclinical studies of new drug compounds at our research facility near Tokyo, Japan, using proven drug discovery techniques and cutting-edge technologies. Our research strategy is to combine in-house and open innovation approaches across target indications.
    We have a solid history of discovering innovative medicines that has led to development and marketing of our products, such as Teribone™, Recomodulin™ Bredinin™, AK1830, AK1320, AK1780, and AK1910.